Quantcast
Last updated on April 19, 2014 at 5:20 EDT

NeuroVive Appoints Chief Operating Officer

February 1, 2013

LUND, Sweden, February 1, 2013 /PRNewswire/ –

NeuroVive, a leading mitochondrial medicine company, is pleased to announce the
appointment of Jan Nilsson as Chief Operating Officer (COO). Jan will oversee the
day-to-day operations of the Company and support the planned commercialisation of
CicloMulsion(R) and NeuroSTAT(R), NeuroVive’s leading products for the treatment of acute
cardiovascular and neurological conditions through mitochondrial protection.

Jan has over 30 years of experience in senior management, commercial and sales roles
in the pharmaceutical and biotechnology sectors in Sweden and internationally. Since 2011
Jan has served as Managing Director of Lipopeptide AB and as Chief Commercial Officer at
Pergamum AB, two clinical-stage Swedish biotech companies developing innovative wound
treatments based on therapeutic peptides. Between 2004 and 2009 Jan served as Managing
Director of Tripep AB, a listed Swedish-biotech company developing therapeutic
DNA-vaccines against hepatitis B and C. Prior to that Jan spent several years at
Schering-Plough where he served in a number of senior management, marketing and sales
positions, including Vice-President for the Nordic region between 2000 and 2004. Jan has
served on the Board of Directors of NeuroVive since 2011. As a result of his new role, Jan
will not be standing for re-election to the NeuroVive Board at the next Annual Meeting.

CicloMulsion(R) and NeuroSTAT(R) are in clinical development by NeuroVive for the
treatment of heart reperfusion injury and traumatic brain injury respectively. These are
indications of huge medical need for which there are currently no approved pharmaceutical
treatment options.

Both products act to prevent the death of mitochondria in damaged cells and the
cascade of intracellular biochemical events that lead to secondary tissue damage following
a traumatic injury. By protecting a cell’s mitochondria NeuroVive’s products ensure that
energy production is preserved and a damaged cell’s normal regenerative mechanisms can act
to repair and maintain the cell.

Mikael Bronnegard, CEO of NeuroVive Pharmaceutical said: “I am delighted to have
appointed Jan Nilsson to the position of Chief Operating Officer, significantly
strengthening our senior management team during what is a very exciting period in
NeuroVive’s development. With CicloMulsion(R) currently in Phase III clinical trial,
NeuroSTAT(R) now entering a Phase IIa clinical study and the recent collaboration
agreement with Sihuan Pharmaceutical for the commercialization of these products in China,
NeuroVive is making significant strides forward in the execution of our product
development and commercial strategies. Jan is an excellent addition to NeuroVive’s
management team and one that will help to drive the Company towards the further
realization of its corporate goals and to maximize shareholder value by delivering our
novel medicines to market.”

About NeuroVive Pharmaceutical AB

NeuroVive Pharmaceutical AB (http://www.neurovive.com) a leading mitochondrial
medicine company is developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection.

NeuroVive’s leading products are special formations of the cyclophilin inhibitor
cyclosporine, which act to limit secondary tissue damage caused by myocardial infarction
and traumatic brain injuries by preventing the destruction of mitochondria in distressed
cells and the cascade of intracellular biochemical events that lead to cell death.

NeuroVive’s lead product is CicloMulsion(R), the first cyclophilin inhibitor for the
treatment of reperfusion injuries. CicloMulsion(R) is currently in a 1000 patient Phase
III clinical trial evaluating its ability to reduce reperfusion injuries in patients with
myocardial infarction.

NeuroVive is also developing NeuroSTAT(R), which is entering a Phase IIa clinical
trial in patients with severe traumatic brain injury. Both indications have huge medical
need and for which there are currently no approved pharmaceutical treatment options.

NeuroVive’s pipeline also includes a cyclophilin inhibitor for stroke and drug
candidates that act on mitochondria to address energy regulation disorders.

NeuroVive’s shares are listed on the Swedish trading platform AktieTorget
(http://www.aktietorget.se). The AktieTorget market is focused on emerging,
entrepreneurial businesses through an electronic trading system supplied by the OMX Nordic
stock exchange in Stockholm, Sweden.

        Media and investor relations contacts

        NeuroVive Pharmaceutical: Mikael Bronnegard
        Email: info@neurovive.com
        Phone No: +46 (0) 70 299 62 64

        Citigate Dewe Rogerson: Nina Enegren / David Dible
        Email: nina.enegren@citigatedr.co.uk
        Phone No: +44 207 282 1050

SOURCE NeuroVive


Source: PR Newswire